Livestream Preview | Enabling the Last Mile for Blockbuster New Drugs with AI

Global expansion has become a key priority in today's healthcare industry. Innovative pharmaceutical companies need to formulate science-based global development strategies that fully account for the characteristics of the drug itself, as well as the medical needs and regulatory environments of different markets, in order to stand out in global competition. At the same time, AI is accelerating the reshaping of drug R&D paradigms and becoming an important driver of clinical research, supporting the full workflow from protocol design to data analysis and accelerating the globalization of innovative drugs.
With the implementation of the 30-day channel policy and the deeper application of AI technologies in clinical research, Chinese innovative drugs are expected to cross the "last mile" more quickly—not only serving patients in China, but also winning global markets amid the wave of overseas expansion. To this end, EClinCloud, in collaboration with Yaorongquan, has invited EClinCloud Founder and CEO Qin Long, EpimAb Biotherapeutics CMO Zhu Yonghong, Alebund Pharmaceuticals Chief Scientific Officer Xiao Shen, and Shanghai Jemincare Pharmaceutical Vice President and Chief Scientist Cui Haifeng to join the Yaodingji livestream to jointly discuss key topics in the global expansion of innovative drugs in the AI era.
Speaker Spotlight
Qin Long
EClinCloud
Founder & CEO
Presentation Topic: New Practices in AI-Driven Global Clinical Research
Dr. Qin Long has over
18 years of experience in the clinical research industry and is a pioneer in promoting and implementing technology solutions such as eCOA, EDC, and CTMS in China's clinical research sector. He has also long focused on the practical application of AI in clinical trial data management and intelligent decision support, advancing the development of a new AI-driven clinical research paradigm. Previously serving as Asia-Pacific head of an international technology company, where he led rapid business growth across the region, he is an entrepreneur driven by academia and science who is passionately committed to shaping future clinical trial models.
Zhu Yonghong
EpimAb Biotherapeutics CMO
Presentation topic: MRCT Clinical Management Strategies and Practice
Dr. Zhu Yonghong has focused on the biopharmaceutical industry for approximately 20 years, with expertise in oncology and immunology and an outstanding track record spanning early- to late-stage program development. Dr. Zhu earned a medical degree (7-year combined program) from the Medical School of Nanjing University and a PhD in microbiology and immunology (specializing in virology) from the University of Rochester School of Medicine and Dentistry. Before joining EpimAb, Dr. Zhu served as CMO of Maxinovel; earlier, Dr. Zhu held leadership positions in areas such as clinical R&D and translational medicine at Roche, Takeda Pharmaceuticals, and Henlius. In these roles, Dr. Zhu made significant contributions in areas including formulating and executing clinical development strategies, as well as evaluating and advancing strategic collaborations.
Xiao Shen
Alebund Pharmaceuticals
Chief Scientific Officer
Presentation Topic: Discussion on Key Points in Global Clinical Development and Registration of Innovative Drugs
Dr. Xiao Shen currently serves as Chief Scientific Officer at Alebund Pharmaceuticals, overseeing preclinical development and global regulatory registration for the company's new drugs and working alongside the Chief Medical Officer to advance their clinical development. Previously, Dr. Xiao served as Chief Medical Officer at Hasten Biopharmaceutical Co., Ltd., and as Chief Strategy Officer and Chief Medical Officer at 3D Medicines. Dr. Xiao Shen previously served at the U.S. Food and Drug Administration (FDA) as a Senior Nonclinical Pharmacology/Toxicology Reviewer responsible for nonclinical review of new drugs for endocrine and metabolic diseases, and as a Senior Clinical Reviewer responsible for clinical review of new drugs for cardiac, renal, and vascular diseases. Over nearly twenty years at the FDA, Dr. Xiao reviewed hundreds of Investigational New Drug (IND) applications across all stages—spanning preclinical, clinical phases, and post-marketing drug efficacy, safety tracking, and follow-up—and served as a clinical reviewer and/or multidisciplinary review team lead responsible for the marketing approval of more than a dozen new drugs. During that period, Dr. Xiao also worked at the FDA Center for Devices and Radiological Health (CDRH), overseeing the review and approval of multiple related medical devices (IDE, 510k, PMA).
Before joining the FDA, Dr. Xiao gained over ten years of clinical practice and laboratory research experience as an attending physician in internal medicine, doctoral research assistant, and postdoctoral fellow, covering the diagnosis and treatment of various general internal medicine conditions, research on the clinical pharmacokinetics of antibiotics, and research on cell signal transduction, among other areas. During that time, in addition to receiving one Third Prize of the National Science and Technology Progress Award and one Second Prize of the All-Army Science and Technology Progress Award, Dr. Xiao also received multiple awards from the FDA, the American Physiological Society (APS), the International Society of Nephrology (ISN), and the Japanese Society for Dialysis and Artificial Organs.
Cui Haifeng
Shanghai Jemincare Pharmaceutical
Vice President and Chief Scientific Officer
Roundtable Topic:
"Going Global" Is an Inevitable Strategic Choice for Chinese Pharmaceutical Companies: Key Points from Strategy to Execution
Dr. Cui Haifeng graduated in chemistry from Zhejiang University,
and in 1997 pursued further studies at the University of Pennsylvania in the United States, earning a PhD in organic chemistry in 2002. Beginning in 2002, he joined GSK in the Philadelphia metropolitan area in the United States to work on novel drug R&D, advancing from Senior Scientist, Researcher, and Principal Scientist to Scientific Director. He led more than ten first-in-class (FIC) new drug programs spanning the full process from target discovery to clinical proof of concept (PoC), and advanced multiple programs into clinical trials, including one at the NDA stage, across disease areas such as cardiovascular disease, infectious diseases, immunology, and oncology. In October 2019, he returned to China and joined the J&J Asia Pacific Innovation Center as Senior Director, responsible for seeking project collaboration opportunities with local innovative companies and research institutes across the Asia-Pacific region in disease areas including infectious diseases and vaccines, neuroscience, cardiovascular and metabolic diseases, and immunology. In March 2021, he joined Shanghai Jemincare under Jemincare as CSO, overseeing overall R&D and focusing on delivering differentiated products and building an internationally competitive R&D pipeline.


